检索结果 - Rebecca Kristeleit

Refine Results
  1. 1
    Optimal treatment for relapsing ovarian cancer

    Optimal treatment for relapsing ovarian cancer 由 JA Ledermann, Rebecca Kristeleit

    出版 2010
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions

    PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions 由 Gottfried E. Konecny, Rebecca Kristeleit

    出版 2016
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  3. 3
    Homologous recombination deficiency and ovarian cancer

    Homologous recombination deficiency and ovarian cancer 由 Jonathan A. Ledermann, Yvette Drew, Rebecca Kristeleit

    出版 2016
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  4. 4
    Mainstreamed genetic testing for women with ovarian cancer: first-year experience

    Mainstreamed genetic testing for women with ovarian cancer: first-year experience 由 Belinda Rahman, Anne Lanceley, Rebecca Kristeleit, Jonathan A. Ledermann, Michelle Lockley, Mary McCormack, Tim Mould, Lucy Side

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    The Tumor Microenvironment of Clear-Cell Ovarian Cancer

    The Tumor Microenvironment of Clear-Cell Ovarian Cancer 由 Michael-John Devlin, Rowan Miller, Florian Laforêts, Panoraia Kotantaki, Dale W. Garsed, Rebecca Kristeleit, David D.L. Bowtell, Jacqueline McDermott, Eleni Maniati, Frances R. Balkwill

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors 由 Geoffrey I. Shapiro, Rebecca Kristeleit, Howard A. Burris, Patricia LoRusso, Manish R. Patel, Yvette Drew, Heidi Giordano, Lara Maloney, Simon P. Watkins, Sandra Goble, Sarah Jaw‐Tsai, Jim Xiao

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors 由 André T. Brunetto, Joo Ern Ang, Rohit Lal, David Olmos, L. Rhoda Molife, Rebecca Kristeleit, Ann Parker, Isabel Casamayor, Muyibat Olaleye, Anna Mais, Bernhard Hauns, Vera Strobel, Bernd Hentsch, Johann S. de Bono

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer

    A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovar... 由 Rebecca Kristeleit, Ірина Давиденко, Vadim Shirinkin, Fatima El-Khouly, Igor Bondarenko, Michael J. Goodheart, В. А. Горбунова, C A Penning, Jack Shi, Xiangdong Liu, Robert Newton, Yufan Zhao, Janet Maleski, Lance Leopold, Russell J. Schilder

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

    A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer 由 Rebecca Kristeleit, Ruth Plummer, Robert H. Jones, Louise Carter, Sarah P. Blagden, Debashis Sarker, Hendrik‐Tobias Arkenau, T.R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara Klencke, Mark Kowalski, Udai Banerji

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

    A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors 由 Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence I. Raynaud, Michelle D. Garrett, Martin Toal, Leon Hooftman, Johann S. de Bono, Jaap Verweij, Ferry A.L.M. Eskens

    出版 2012
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer

    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer 由 Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A. McNeish, Rosalind Glasspool, Marcia Hall, René L. Roux, Agnieszka Michael, Andrew R. Clamp, Gordon C. Jayson, Rebecca Kristeleit, Susana Banerjee, Anita Mansouri

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer

    Pembrolizumab in Patients With Advanced Clear Cell Gynecological Cancer 由 Rebecca Kristeleit, Michael-John Devlin, Andrew R. Clamp, Charlie Gourley, René L. Roux, Marcia Hall, Rachel Nirsimloo, Valentinos Kounnis, Lesley Sage, Priya Narayanan, C. Simon Herrington, Rupali Arora, Laura Farrelly, Laura Hughes, Nicholas Counsell, Rowan Miller

    出版 2025
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

    Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced... 由 Johann S. de Bono, Rebecca Kristeleit, Anthony W. Tolcher, Peter C.C. Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan B. Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers 由 Rebecca Kristeleit, Alexandra Léary, Ana Oaknin, Andrés Redondo, Angela George, Jane Yuet Ching Hui, Aicha Seiller, Mario Liste-Hermoso, J. Willis, Colby S. Shemesh, Jim Xiao, Kevin K. Lin, Luciana Molinero, Yinghui Guan, Isabelle Ray‐Coquard, Linda Mileshkin

    出版 2024
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer

    ARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer 由 Rebecca Kristeleit, Domenica Lorusso, Ana Oaknin, Tamar Safra, Elizabeth M. Swisher, Igor Bondarenko, Tomasz Huzarski, Jaroslav Klát, Vladimir Moiseyenko, Ròbert Póka, Luciana Spillari Viola, Chris Tankersley, Lara Maloney, Sandra Goble, Caro Unger, A. Dowson, Heidi Giordano, Amit M. Oza

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Detection of circulating tumour cell clusters in human glioblastoma

    Detection of circulating tumour cell clusters in human glioblastoma 由 Ilona Krol, Francesc Castro-Giner, Martina Maurer, Sofia Gkountela, Barbara M. Szczerba, Ramona Scherrer, Niamh Coleman, Suzanne Carreira, Felix Bachmann, Stephanie Anderson, Marc Engelhardt, Heidi A. Lane, T.R. Jeffry Evans, Ruth Plummer, Rebecca Kristeleit, Juanita Lopez, Nicola Aceto

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors

    A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advance... 由 Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan W. Smit, Ann Forslund, Charles E. Phelps, A. John Camm, T.R. Jeffry Evans, Johann S. de Bono, Udai Banerji

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study

    O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study 由 Rebecca Kristeleit, Alla Lisyanskaya, А. А. Феденко, Mikhail Dvorkin, Andréia Cristina de Melo, Y. Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, Luciano Biela, M. Nechaeva, Francesco Raspagliesi, Giovanni Scambia, David Cibula, Ròbert Póka, Ana Oaknin, Tamar Safra, Beata Maćkowiak-Matejczyk, Ling Ma

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors

    First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors 由 Elizabeth J. Davis, Juan Martín-Liberal, Rebecca Kristeleit, Daniel C. Cho, Sarah P. Blagden, Dominik Berthold, Dana B. Cardin, María Vieito, Rowan Miller, Prashanth Hari Dass, Angela Orcurto, Kristen Spencer, John E. Janik, Jason A. Clark, Thomas Condamine, Jennifer Pulini, Xuejun Chen, Janice M. Mehnert

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma

    Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma 由 Susana Banerjee, Gaia Giannone, Andrew R. Clamp, Darren Ennis, Rosalind Glasspool, Rebecca Herbertson, Jonathan Krell, Ruth Riisnaes, Hasan Mirza, Zhao Cheng, Jacqueline McDermott, Clare Green, Rebecca Kristeleit, Angela George, Charlie Gourley, Liz-Anne Lewsley, Debbie Rai, Udai Banerji, Samantha Hinsley, Iain A. McNeish

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: